Galectin Therapeutics Inc. (GALT)

[thefamilyman]

Cellceutix did a Phase 2 POC testing Prurisol against psoriasis. They based the dosing (50, 100, and 200mg arms) for that trial on the results from the animal studies. The 50 and 100mg arms performed no better than the placebo. Only the 200mg showed positive (very positive) results. They are about to start a Phase 2b with 200, 300, and 400mg arms.

I tell that story because I suspect that GALT may be experiencing something similar with GR-MD-02 on their liver (and possibly psoriasis) trials. The animal studies apparently led GALT to also underestimate the appropriate dosage level for humans. I hope the CX trial is successful, but while we wait I hope they do whatever is necessary to get higher doses of GR-MD-02 through Phase 1 testing. A Phase 1 like was done previously is relatively cheap, quick, and still offers the possibility of efficacy as a secondary outcome.


"Exciting time for Galectin. Will 2017 deliver a new beginning and revival or the end? The skin disease drug commercials on TV are littered with side effects warnings that sound worse that the skin disease its supposed to cure. Galctin returns to the lab to optimize the dosing regimen for GR MD 02 and increasing drug exposure. It's about time!!!!!" - rickyricks